^
Association details:
| Biomarker: | HIF1A overexpression |
|---|---|
| Cancer: | Squamous Cell Carcinoma of Head and Neck |
| Drug: | TheraCIM (nimotuzumab) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Prognostic and predictive significance of nuclear HIF1a expression in locally advanced HNSCC patients treated with chemoradiation with or without nimotuzumab.
Excerpt:
Treatment-naive tumour tissue samples of 404 patients, a subset of randomised Phase 3 trial comparing cisplatin radiation (CRT) versus nimotuzumab plus cisplatin radiation (NCRT) were analysed to evaluate the expression of HIF1α…High HIF1α expression is a predictor of poor clinical response to CRT in HPV-negative LA-HNSCC patients. These patients with high HIF1α significantly benefited with the addition of nimotuzumab to CRT.
Secondary therapy:
cisplatin
DOI:
https://doi.org/10.1038/s41416-020-01064-4
